Search results


Authorize the processing of personal data
Edit email address
Invalid email
Email Sent
Authorize the processing of personal data
You searched for:
Results: 60
1

Respiratory

hiesi Farmaceutici is fully committed to the care and improvement of the quality of life of people suffering from respiratory diseases including asthma and COPD (Chronic Obstructive Pulmonary Disease). Asthma and COPD are characterised by a reduction in the respiratory flow although they are driven...
2

Neonatology

Normally, delivery takes place between the 37th and the 42nd week of gestation. By that time, the foetus is fully formed and developed enough to be able to adapt to extra-uterine life. However, in some cases delivery may occur before the 37th week of gestation. In that case, the neonate is...
3

Neurology

-
4

Pharmacovigilance

Chiesi Group pays great attention to the safety of its products. Following ethical principles and Russian legislation requirements, Chiesi Group collects and analyses information on adverse events, as well as maintains effective cooperation with regulatory authorities in this field. Timely...
5

History

-
6

Mission and values

-
7

Contacts

-
8

Research and development

nnovation is the driving force behind every technologically advanced industry, but for the pharmaceutical industry it plays a vital role since it concerns the health and quality of life of people. For Chiesi, Research and Development are a true human and technological asset and, together with...
9

Clinical trial transparency

Running clinical trials and obtaining results is what clinical development is all about. Sharing results is very important too. Chiesi Farmaceutici S.p.A. and its affiliated companies (Chiesi) are EPFIA members, and therefore are committed to clinical trial transparency. Currently all Chiesi...
10

Production plants

hiesi Group has three production plants:  Parma, Italy....
11

Therapeutic Areas

-
12

Certification of working conditions

As of January 1, 2014, Federal Law No. 426-FZ of December 28, 2013, "On the Special Assessment of Working Conditions" (hereinafter Federal Law No. 426-FZ), came into force, in accordance with which, instead of certifying workplaces according to working conditions (ARM), employers are obliged to...
13

Commercial partners

ООО «Сhiesi Pharmacuiticals» is the Party of the Code of Good Practice in the Pharmaceutical Industry. Whereas Russian law does not directly regulate certain aspects of the relationship between drug manufacturers and the various categories of buyers of medicines; Whereas the...
14

Medical devices

-
15

Ethics

Ethics is a branch of philosophy that deals with human behavior and it expresses a set of rules of conduct which should be applied in everyday actions to contribute to the common good. Chiesi has long been in line with these general ethical principles: we want to affirm our values, build our...
16

News

-
17

Press release

Press release
18

Prescription products

-
19

Vacancies

For every employee in the Group we follow the principles of equal opportunities for everyone, mutual respect and trust along with continuous look for ways excellence. One of our key Values is people. If you wish to develop and grow professionally, if you are looking for a work in a driving team...
20

Work in Chiesi

Chiesi Russia is a solid and effective team of 170+ people. Our representatives work in 37 Russian cities. Comfortable and open working environment, high ethical standards of prescription drugs promotion , friendliness and clarity of set objectives are the basis of our company.  Here is space...
21

Reward, compensation and benefits

The success of the company development and promotion of our products also depends on the well-being and satisfaction of our employees, and Chiesi believes that one of its tasks is providing its employees with valuable benefits, which meet the needs of each of us.   We offer successful...
22

Trainings and career development

    We consider it very important that conditions for further personal and professional development are created for each employee. For this, the company has various possibilities.   We aim to to ease the process of adaptation for "newcomers" so that our new colleagues can quickly...
23

Career growth opportunities

Our company is growing and is actively expanding in the Russian market. One of the priorities for Chiesi Russia and the whole Chiesi Group is employee development . The main objectives of this process are the improvement of professional skills and competencies, the upbringing of a team capable of...
24

Pipeline

R&D Pipeline: balanced with focus   The number of research and development programmes is increasing year by year with a strong focus in three key areas: respiratory, neonatology and special care.   RESPIRATORY Respiratory is a core area of R&D expertise, which has delivered...
25

AIPM Membership

Chiesi Pharmaceuticals LLS as an AIPM member company recognizes their responsibility to society. On this basis,  Chiesi Pharmaceuticals LLS  accepts and undertakes fulfill the requirements of the AIPM Code of Practice and to follow it not only in letter but also in spirit.   Chiesi...
26

ENVIROMENT AND SAFETY

27

The Chiesi Foundation

Founded in 2005, the Chiesi Foundation Onlus is a no-profit organisation which seeks to capitalise on Chiesi’s legacy of knowledge in order to promote health and alleviate the suffering of patients affected by chronic obstructive respiratory diseases, rare diseases and neonatal diseases. The...
28

Disclosure of information about the transfer of values in favor of HCP’s and HCO’s.

In accordance with the requirement of Chapter 7 "Disclosure of information about the transmission of values in favor of specialists and health care organizations" code of good practice of the Association of international pharmaceutical manufacturers (AIPM), "Chiesi Pharmaceuticals" LLC publishes on...
29

Term of use

-
30

Sitemap

-
31

Links

-
32

Foto

-
33

Search Result

-
34

Annual report e brochures

-
35

--

-
36

About us

We are an international company based in Parma, with more 80 years of experience and a strong focus on research, development, production and the commercialisation of innovative medicines in the Respiratory, Neonatology, Rare Disease and Special Care Therapeutic Areas.
37

List of events

-
38

konfidencialnost

-
39

Test

-
40

80 years of innovation and success in healthcare: Chiesi reports significant international growth in 2015

Chiesi Farmaceutici generated just under €1.5bn in revenue in 2015, a year-on-year increase of almost 10%. The international footprint of the Group continues to grow: 80% of turnover is now from the non-Italian market. The expansion of Chiesi’s US affiliate is extremely...
41

Chiesi certified Top Employer also for 2017

Chiesi is Top Employer Italy for the ninth consecutive year and Top Employer Europe for the fifth consecutive year, confirming to be among the entrepreneurial excellence for the working conditions of its employees. It is the independent research of the Top Employers Institute to certify it, which...
42

Alberto, Paolo and Andrea Chiesi winners of the “Entrepreneur of the year 2015” Award

Alberto, Paolo and Andrea Chiesi are the National winners of the EY “ L’Imprenditore dell’Anno 2015”  Award. The prestigious recognition, promoted by EY-Ernst & Young and sponsored by Azimut Wealth Management, is now at its 19th edition. The...
43

refer

-
44

80 years of innovation and success in healthcare: Chiesi reports significant international growth in 2015

-
45

Europe approves Holoclar®, the first stem cell—based medicinal product

Parma/Modena (Italy), February 20, 2015 – The European Commission has granted a conditional marketing authorization, under Regulation (EC) No 726/2004, to Holoclar®, an advanced therapy based on autologous stem cells and capable to restore the eyesight of patients with severe cornea...
46

reward

-
47

In Russia, a new drug for the treatment of bronchial asthma

-
48

Chiesi Farmaceutici and Cornerstone Therapeutics Announce Agreement For a Merger Transaction

Chiesi Farmaceutici S.p.A. (“Chiesi”), a leading European pharmaceutical company, and Cornerstone Therapeutics Inc. (NASDAQ: CRTX) (“Cornerstone”), a specialty pharmaceutical company focused on commercializing products for the U.S. hospital and adjacent specialty markets,...
49

Chiesi Group receives the European Marketing Authorisation for Trimbow® (inhaled corticosteroid / long-acting β2-agonist / long-acting muscarinic antagonist)

Parma, Italy, July 24 2017 Chiesi Group (Chiesi), an international research-focussed healthcare company, today announced that the European Commission has granted the marketing authorisation for Trimbow® for the maintenance treatment in adult patients with moderate to severe chronic obstructive...
50

Foster

-
51

Atimos

-
52

Curosurf

-
53

Ortokine

-
54

Gianeb

-
55

Ignisen

-
56

-

-
57

-

-
58

-

-
59

-

-
60

ORTHOKINE®

-